Edition: India  
 
> >

Merck to halt study of mild to moderate Alzheimer's drug

Reuters India Tuesday, 14 February 2017
(Reuters) - Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness.
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 
Source: Wochit News - < > Embed

News video: Scientists Disappointed After New Alzheimer's Drug Failed

Scientists Disappointed After New Alzheimer's Drug Failed 00:35

Researchers found that the new promising Alzheimer’s drug verubecestat did not work. Dr. Roger Perlmutter, president of Merck Research Laboratories, stated, “While we are disappointed that a benefit was not observed in this study, our work continues [to study the impact of] verubecestat in people...

You Might Like


Other recent news in Health

Owner of Farsi Language Satellite Network Killed in TURKEYTrump: 'Would Not Be Happy' with Another NORTH KOREA Nuclear Test
For RUSSIA and US, Uneasy Cooperation on Cybercrime Is Now a Mess British PM May Braces for Difficult BREXIT Negotiations
Late-night TV Host SAMANTHA BEE's Show Briefly Upstages Correspondents' DinnerPeople's CLIMATE MARCH Brings Thousands to Washington
Ancient Gold Angkorian Jewelry to Return to Cambodia From LONDONTrump Invites Philippines DUTERTE TO WHITE HOUSE
THE GODFATHER’ at 45: The Trials, Inspiration Behind the FilmTexas TORNADO Leaves Deaths, Dozens Injured

Twitter

Environmentally friendly: newsR is hosted on servers powered solely by renewable energy
© 2017 newsR / One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter